Clinical pharmacology and pharmacogenetics of gemcitabine.
Gemcitabine is a cytotoxic nucleoside analog, which is widely used in the treatment of malignancies. Interindividual differences in gemcitabine pharmacokinetics and pharmacodynamics have been demonstrated. Pharmacogenetic factors may account for a significant proportion of these differences. This review provides an update on the pharmacogenetics of gemcitabine and its influence on gemcitabine efficacy and toxicity.
Wong
Andrea
A
Department of Hematology-Oncology, National University Hospital, Singapore.
Soo
Ross A
RA
Yong
Wei-Peng
WP
Innocenti
Federico
F
D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics / Q000494:pharmacology / Q000633:toxicity; D003564:Cytidine Deaminase / Q000235:genetics / Q000378:metabolism; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000633:toxicity; D003842:Deoxycytidine Kinase / Q000235:genetics / Q000378:metabolism; D005006:Ethnicity / Q000235:genetics; D006801:Humans; D033703:Nucleoside Transport Proteins / Q000235:genetics / Q000378:metabolism; D009708:Nucleotidases / Q000235:genetics / Q000378:metabolism; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D012264:Ribonucleotide Reductases / Q000235:genetics / Q000378:metabolism; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D033703:Nucleoside Transport Proteins; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D003842:Deoxycytidine Kinase; D009708:Nucleotidases; D003564:Cytidine Deaminase; D000093542:Gemcitabine